Entering text into the input field will update the search result below

ZymoGenetics (ZGEN) +59% premarket after Bristol-Myers (NYSE:BMY) pays $85M for its experimental...

Jan. 13, 2009 9:02 AM ETZymoGenetics, Inc. (ZGEN-OLD) StockBMY, ZGEN-OLDBy: Eli Hoffmann, SA News Editor1 Comment
ZymoGenetics (ZGEN) +59% premarket after Bristol-Myers (NYSE:BMY) pays $85M for its experimental hepatitis C treatment up front, and could pay as much as $1.1B based on future milestones.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ZGEN-OLD--
ZymoGenetics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.